Industry News
mRNA Vaccines and Pancreatic Cancer: One Patient's Story Fuels Hope
It has been a big year for mRNA cancer vaccines, the same technology behind many COVID-19 shots. Merck and Moderna recently reported the first major successful trial of an mRNA vaccine for melanoma, showing meaningful reductions in recurrence and death. Now, attention is turning to what this approach could mean for pancreatic cancer.
NPR shares the story of Donna Gustafson, who seven years ago became the first person in the world to receive an mRNA vaccine designed to treat pancreatic cancer.
Diagnosed at 66, she is now 72 and shows no evidence of the disease.
Unlike off-the-shelf vaccines, these mRNA vaccines are personalized. After a patient's tumor is surgically removed, its genetic information is used to create a vaccine tailored to that individual. Researchers are still working to understand why some patients respond strongly while others don't, and larger trials are underway. The National
Cancer Institute is also partnering with private companies to speed up development of more mRNA cancer vaccines.
Stories like Donna's are a powerful reminder of why continued research matters.
Read the full article: https://www.sciencealert.com/new-pancreatic-cancer-vaccine-sparked-immune-responses-in-99-of-patients
.png)
.png)














.png)






